UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
11 avr. 2024 23h07 HE
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
05 avr. 2024 16h21 HE
|
Predicine
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
05 avr. 2024 16h10 HE
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
05 avr. 2024 02h08 HE
|
Predicine
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting...
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
08 janv. 2024 12h01 HE
|
Predicine
Collaboration Utilizing PredicineCARE™ Urine cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC
11 déc. 2023 15h12 HE
|
Predicine
HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib...
Predicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023
17 oct. 2023 13h58 HE
|
Predicine
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid,...
Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib
20 sept. 2023 13h12 HE
|
Predicine
HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine (NEJM),...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
28 avr. 2023 17h42 HE
|
Predicine
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 Conference
14 avr. 2023 16h47 HE
|
Predicine
HAYWARD, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present data from 12 studies and introduce PredicineALERT™, a...